GLPwatch
Mounjaro for Alcohol use disorder
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for alcohol use disorder, and any use for this condition is off-label or investigational. Research suggests tirzepatide may reduce alcohol consumption in animal models and in individuals with obesity, but these findings are not conclusive for human treatment.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Alcohol use disorder |
| Approval status | Investigational / off-label |
| Research papers | 5 |
Mounjaro is not FDA-approved for alcohol use disorder; the research below reflects investigational or off-label study only.
Research on tirzepatide for alcohol use disorder (5)
- Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.
- Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy.
- Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.
- Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.
- Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.